PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (15,19–22). Whereas HEY-CTLshRNA cells were practically insensitive to APR-246, HEY-CIP2AshRNA cells showed a >50% reduction in cell viability (Fig. 1A).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [15]
In the citing paper
“The small molecule APR-246 (PRIMA-1Met) can reactive mutant p53 in tumor cells and trigger cell death by apoptosis.”
From Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 (2018) · cites this paper as [7]
In the citing paper
“Importantly, PRIMA-1 and its structural analog PRIMA-1MET (APR-246) inhibited tumor growth in mouse models of GBM [124,129,130].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [129]
In the citing paper
“Although APR-246 was originally identified as a compound that reactivates mutant TP53 (15,16,20), the tested OvCa cell lines displaying hypersensitivity to APR-246 upon CIP2A inhibition, exhibit varying TP53 mutation statuses.”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (14)(15)(16)(17)(18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In addition, p53 can transrepress some genes, for instance the antiapoptotic Bcl-2 gene, the IGF1 receptor, MAP4, and hTERT (Vogelstein et al., 2000).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“…protein induces cell cycle arrest and/or cell death by apoptosis in response to various forms of cellular stress, for example, DNA damage and oncogene activation (Vousden and Lu, 2002). p53 elicits these responses through transcriptional regulation of a large number of downstream effector genes.”
BackgroundAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183 · cited 1×
“Likewise, several clinical studies have indicated that anticancer drugs preferentially target wild-type p53carrying breast tumors (Bergh et al., 1995; O’Connor et al., 1997; Weinstein et al., 1997; Borresen-Dale, 2003).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“Our previous studies indicated that tumor cells expressing high levels of mutant p53 are more sensitive to PRIMA-1 (Bykov et al., 2002a).”
BackgroundInfluentialSelf-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“Studies in cultured human tumor cells and various mouse tumor models have shown that inactivation of p53 reduces or abrogates the apoptotic response to chemotherapy (Bunz et al., 1999; Keshelava et al., 2001; Schmitt, 2003).”
BackgroundPharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799 · cited 9×
“Interestingly, CP-31398 that was shown to induce p53 levels through inhibition of p53 ubiquitination (Wang et al., 2003) induced mutant p53 levels and phosphorylation of p53 at Ser15 in H1299-His175 cells and showed synergy with PRIMA-1MET in mutant p53-expressing cells.”
BackgroundInfluentialThe p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765 · cited 1×
“The p53-induced MDM2 gene regulates p53 turnover via a negative feedback loop that ensures low levels of p53 in the absence of stress signaling (Michael and Oren, 2003).”
BackgroundBergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408 · cited 1×
“Cisplatin has been shown to induce p73-dependent apoptosis (Irwin et al., 2003).”
BackgroundBørresen-Dale, A.-L. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 354
Cited by
Items 101–200 of 255
p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
Teoh, P. J., & Chng, W. J. (2014) · BioMed Research International · doi:10.1155/2014/717919 · Cited by 60
Marret, G., Bièche, I., Dupain, C., Borcoman, É., du Rusquec, P., Ricci, F., Hescot, S., Sablin, M., Tresca, P., Bello, D., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00280 · Cited by 60
Erratum: PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2016) · Oncogene · doi:10.1038/onc.2016.210 · Cited by 55
Self-citationRetractedRUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response
Ozaki, T., Nakagawara, A., & Nagase, H. (2013) · International Journal of Genomics · doi:10.1155/2013/271347 · Cited by 58
“found a remarkable synergistic effect in vitro between PRIMA-1Met and various antitumor drugs including cisplatin (CDDP), adriamycin (ADR), and camptothecin (CPT) [95].”
BackgroundMenichini, P., Monti, P., Speciale, A., Cutrona, G., Matis, S., Fais, F., Taiana, E., Neri, A., Bomben, R., Gentile, M., et al. (2021) · Cells · doi:10.3390/cells10010098 · Cited by 48
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2008) · Oncogene · doi:10.1038/onc.2008.249 · Cited by 57
“In agreement with our earlier results (Bykov et al., 2005a), PRIMA-1MET induced expression of both Bax and PUMA in a mutant p53-dependent manner in the H1299 cells.”
BackgroundMethodResultSelf-citationRetractedAli, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 52
Breathing new insights into the role of mutant p53 in lung cancer
Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G., & Sutherland, K. D. (2025) · Oncogene · doi:10.1038/s41388-024-03219-6 · Cited by 46
Golubovskaya, V., & Cance, W. G. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.003 · Cited by 51
PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status
Supiot, S., Zhao, H. W., Wiman, K. G., Hill, R. P., & Bristow, R. G. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.01.001 · Cited by 45
“Therefore, the sensitization occurred independent of re-activation of p21-induced cell-cycle arrest or apoptosis, which is in contrast to studies of cisplatinum toxicity in p53Null cells with this agent [7].”
BackgroundResultSelf-citationImportance of p53 for cancer onset and therapy
Haupt, S., & Haupt, Y. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000217422.52208.fa · Cited by 48
Zhang, J., Yu, G., Yang, Y., Wang, Y., Guo, M., Yin, Q., Yan, C., Tian, J., Fu, F., & Wang, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106128 · Cited by 44
Patyka, M., Sharifi, Z., Petrecca, K., Mansure, J., Jean-Claude, B., & Sabri, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11197 · Cited by 42
“PRIMA-1 (p53 reactivation and induction of massive apoptosis) and its methylated and more active form PRIMA-1MET (APR-246) identified by Bykov and colleagues restore mutp53 activity by promoting proper folding of the mutant protein [29, 30].”
BackgroundA thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41
“APR-246 sensitivity is dependent on the presence of mutant p53, cellular thiol status, and drug accumulation Cells expressing mutant p53 were more sensitive to APR-246 than cells lacking p53 (Appendix Table S1, Figs 5A and EV5A), in agreement with our previous data (Bykov et al, 2005).”
ResultSelf-citationMetabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 43
“PRIMA-1MET, a methylated analog of PRIMA-1, is more potent and has better permeability than PRIMA-1 [335,336].”
BackgroundNovel ovarian cancer maintenance therapy targeted at mortalin and mutant p53
Ramraj, S. K., Elayapillai, S. P., Pelikan, R. C., Zhao, Y. D., Isingizwe, Z. R., Kennedy, A. L., Lightfoot, S. A., & Benbrook, D. M. (2020) · International Journal of Cancer · doi:10.1002/ijc.32830 · Cited by 46
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 43
p73 as a Pharmaceutical Target for Cancer Therapy
Bisso, A., Collavin, L., & Sal, G. D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222667 · Cited by 43
YOSHIKAWA, N., KAJIYAMA, H., NAKAMURA, K., UTSUMI, F., NIIMI, K., MITSUI, H., SEKIYA, R., SUZUKI, S., SHIBATA, K., CALLEN, D., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4653 · Cited by 40
Pharmacological Activation of p53 in Cancer Cells
Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 47
Restoration of Wild‐Type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy
Wiman, K. G. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97014-6 · Cited by 40
Self-citationRoh, J.-L., Ko, J. H., Moon, S. J., Ryu, C. H., Choi, J. Y., & Koch, W. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.020 · Cited by 44
Wallerand, H., Reiter, R. E., & Ravaud, A. (2008) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283097889 · Cited by 39
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Advances in sarcoma gene mutations and therapeutic targets
Gao, P., Seebacher, N. A., Hornicek, F. J., Guo, Z., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.001 · Cited by 38
The molecular genetics of breast cancer and targeted therapy.
Suter, R., & Marcum, J. A. (2007) · PubMed Central · Cited by 56
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35
Self-citationGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Whitsett, T. G., Richer, A. L., Friel, J. M., Carson, V. M., & Inge, L. J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52845 · Cited by 42
Kobayashi, T., Makino, T., Yamashita, K., Saito, T., Tanaka, K., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K., Morii, E., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01561-0 · Cited by 36
Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1080 · Cited by 35
p73: From the p53 shadow to a major pharmacological target in anticancer therapy
Ramos, H., Raimundo, L., & Saraiva, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105245 · Cited by 35
A BODIPY‐Based 1D Covalent Organic Framework for Photocatalytic Aerobic Oxidation
Zhao, J., Xie, M., Chen, X., Jin, J., Zhao, W. J., Luo, J., Ning, G., Liu, J., & Li, D. (2023) · Chemistry - An Asian Journal · doi:10.1002/asia.202300328 · Cited by 33
Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Zhang, W., Yi, B., Wang, C., Chen, D., Bae, S., Wei, S., Guo, R., Lu, C., Nguyen, L. L. H., Yang, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1927 · Cited by 33
Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future
Choi, J., Shukla, M., & Abdul‐Hay, M. (2023) · Acta Haematologica · doi:10.1159/000531628 · Cited by 36
Magri, J., Gasparetto, A., Conti, L., Calautti, E., Cossu, C., Ruiu, R., Barutello, G., & Cavallo, F. (2021) · Cells · doi:10.3390/cells10010108 · Cited by 34
PRIMA‐1 synergizes with adriamycin to induce cell death in non‐small cell lung cancer cells
Magrini, R., Russo, D., Ottaggio, L., Fronza, G., Inga, A., & Menichini, P. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21794 · Cited by 36
PRIMA-1MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins
Rökaeus, N., Klein, G., Wiman, K. G., Székely, L., & Mattsson, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209858 · Cited by 33
Self-citationThe Development of p53-Targeted Therapies for Human Cancers
Lu, Y., Wu, M. Y., Xu, Y., & Yu, L. (2023) · Cancers · doi:10.3390/cancers15143560 · Cited by 32
“The addition of a methyl group to PRIMA-1 led to APR-246, also known as PRIMA-1MET, which increased the pro-apoptotic activity and membrane permeability of the compound [44].”
BackgroundNovel p53 therapies for head and neck cancer
Castellanos, M. R., & Pan, Q. (2016) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2016.05.005 · Cited by 34
“The anti-tumor efficacy of cisplatin was potentiated with PRIMA-1 in mutant p53 (H175) H1299 lung carcinoma cells in vitro and in vivo.(34) In addition, PRIMA-1 cooperated with cisplatin to induce Bax and PUMA in a mutant p53-dependent context.”
BackgroundMethodInfluentialp53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Teoh, P. J., Bi, C., Sintosebastian, C., Tay, L. S., Fonseca, R., & Chng, W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11241 · Cited by 28
“Although PRIMA-1 has been reported to synergize with various cytotoxic drugs such as dexamethasone, doxorubicin and cisplatin [14, 16, 48], to the best of our knowledge, our study is the first to report the novel efficacy of PRIMA-1-bortezomib combination.”
BackgroundGOF Mutant p53 in Cancers: A Therapeutic Challenge
Dolma, L., & Muller, P. A. J. (2022) · Cancers · doi:10.3390/cancers14205091 · Cited by 31
Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
Lieschke, E., Wang, Z., Kelly, G. L., & Strasser, A. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy077 · Cited by 30
“cancer-derived cell lines in a manner dependent on mutant p53 (Bykov et al., 2005; Zandi et al., 2011; Duffy et al., 2017), but there are also reports that this compound can inhibit the growth of tumour cells in a p53-independent manner (Saha et al.”
BackgroundTherapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 34
Why is Mortalin a Potential Therapeutic Target for Cancer?
Yoon, A., Wadhwa, R., Kaul, S., & Yun, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.914540 · Cited by 19
Breaking Tolerance in a Mouse Model of Multiple Myeloma by Chemoimmunotherapy
Sharabi, A., & Haran‐Ghera, N. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07001-6 · Cited by 29
PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax
Wang, T., Lee, K., Rehman, A., & Daoud, S. S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.006 · Cited by 26
Mouse models of sarcomas: critical tools in our understanding of the pathobiology
Post, S. M. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-20 · Cited by 29
“Preclinical drugs like PRIMA1-Met and NCS319726 have been shown to restore mutant p53 activities [74,75].”
BackgroundRedox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
Butturini, E., Butera, G., Pacchiana, R., de Prati, A. C., Mariotto, S., & Donadelli, M. (2021) · Cells · doi:10.3390/cells10113149 · Cited by 28
p53 biology and reactivation for improved therapy in MDS and AML
Zawacka‐Pankau, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00579-9 · Cited by 28
Roh, J.-L., Kim, E. H., Park, H., & Park, J. Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.488 · Cited by 26
“of other p53-reactivating small molecules to synergize with the conventional chemotherapeutic agents.(18,19,36) Taken together, these findings may be of paramount clinical significance:”
BackgroundKobayashi, N., Abedini, M. R., Sakuragi, N., & Tsang, B. K. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-7 · Cited by 26
“PRIMA-1 synergizes with chemotherapeutic drugs to induce tumor cell apoptosis [12,19-21].”
BackgroundThe Targeted Therapies for Osteosarcoma via Six Major Pathways
Wang, S., Ren, Q., Li, G., Zhao, X., Zhao, X., & Zhang, Z. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230821142839 · Cited by 35
Targeting the molecular effects of a hypoxic tumor microenvironment
Cárdenas-Navia, L. I. (2007) · Frontiers in bioscience · doi:10.2741/2372 · Cited by 27
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
Mlakar, V., Jurkovic Mlakar, S., Lesne, L., Marino, D., Rathi, K. S., Maris, J. M., Ansari, M., & Gumy-Pause, F. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1066-6 · Cited by 25
DNA-damage sensitizers: Potential new therapeutical tools to improve chemotherapy
Michod, D., & Widmann, C. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.003 · Cited by 31
“[89] Bykov VJ, Zache N, Stridh H, et al.”
BackgroundDisarming mutant p53 oncogenic function
Girardini, J. E., Marotta, C., & Sal, G. D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.003 · Cited by 31
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911023 · Cited by 24
“Clinical trials using APR-246 alone or in combination with other drugs due to the ability to target mutp53 are underway (ClinicalTrials.gov Identifiers: NCT04383938, NCT04990778, NCT04419389, NCT03268382, NCT00900614, NCT02098343, NCT04214860, NCT02999893, NCT03072043, NCT03588078, NCT03745716, NCT03391050, NCT0393129…”
BackgroundInfluentialAhmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 26
Ikeda, D., Chi, S., Uchiyama, S., Nakamura, H., Guo, Y., Yamauchi, N., Yuda, J., & Minami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115950 · Cited by 28
Autophagic Organelles in DNA Damage Response
Kim, J., Lee, S.-M., Kim, H., Lee, H., Seong, K. M., Youn, H., & Youn, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668735 · Cited by 22
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 23
Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant
Li, W., Li, L., Yang, H., Shi, C., Lei, Z., Guo, L., & Wang, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907272 · Cited by 26
Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Lopes, E. A., Gomes, S., Saraiva, L., & Santos, M. M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867325666181116124308 · Cited by 14
Systemic Treatments for Inflammatory Breast Cancer
Yang, C. H., & Cristofanilli, M. (2006) · Breast Disease · doi:10.3233/bd-2006-22107 · Cited by 20
Patented small molecule inhibitors of p53–MDM2 interaction
Deng, J. N., Dayam, R., & Neamati, N. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.2.165 · Cited by 19
Timofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 19
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 19
Cory, A. H., Chen, J., & Cory, J. G. (2006) · PubMed · Cited by 18
Qayoom, H., & Mir, M. A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117351 · Cited by 18
da Paz, M. M., Ferretti, G. D. S., Martins-Dinis, M. M. D. C., Ferreira, B. I. S., Faier-Pereira, A., Barnoud, T., Moreira, O. C., Silva, J. L., Cordeiro, Y., & Rangel, L. P. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1165132 · Cited by 18
“Other reports have described the benefits of this combination in vitro and in vivo, with PRIMA-1 and PRIMA-1 in different tumor models (Bykov et al., 2005; Roh et al., 2011; Mssina et al., 2012; Kobayashi et al., 2013).”
BackgroundSpecifically targeted gene therapy for small-cell lung cancer
Christensen, C. L., Zandi, R., Gjetting, T., Cramer, F., & Poulsen, H. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.10 · Cited by 17
XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer
Roh, J., Park, J. Y., & Kim, E. H. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1026-8 · Cited by 18
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer
Bos, T., Ratti, J. A., & Harada, H. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.676643 · Cited by 17
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., et al. (2021) · Cancers · doi:10.3390/cancers13174476 · Cited by 14
PTC596-Induced BMI-1 Inhibition Fights Neuroblastoma Multidrug Resistance by Inducing Ferroptosis
Valenti, G. E., Roveri, A., Venerando, R., Menichini, P., Monti, P., Tasso, B., Traverso, N., Domenicotti, C., & Marengo, B. (2023) · Antioxidants · doi:10.3390/antiox13010003 · Cited by 17
“…several strategies have been proposed to restore P53 function and, among the compounds developed for the reactivation of mutated P53 [10], PRIMA-1 MET (2-(hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one or APR-246) has been shown to boost antitumor activity in several cancer cells [11–14].”
BackgroundMethodTranscriptional Regulation of Amino Acid Transport in Glioblastoma Multiforme
Umans, R. A., Martin, J., Harrigan, M. E., Patel, D. C., Chaunsali, L., Roshandel, A. K., Iyer, K. V., Powell, M. D., Oestreich, K. J., & Sontheimer, H. W. (2021) · Cancers · doi:10.3390/cancers13246169 · Cited by 14
“Tumors were allowed to establish for 7 days until animals were randomly assigned to one of two retro-orbital (RO) treatment groups: (1) sterile saline, or (2) 100 mg/kg PRIMA-1Met (Cayman Chemical, Ann Arbor, MI, USA, #9000487), as used in previous experiments [20].”
MethodAnticancer therapeutic strategies for targeting mutant p53-Y220C
Chasov, V. V., Davletshin, D., Gilyazova, E., Mirgayazova, R., Kudriaeva, A. A., Khadiullina, R., Yuan, Y., & Bulatov, E. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230093 · Cited by 14
Saxena, K., & Konopleva, M. Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804856 · Cited by 14
Key genes altered in glioblastoma based on bioinformatics (Review)
Ghafari, M. A., Jaafari, N. E., Mouallem, M., Maassarani, T., El‐Sibai, M., & Abi‐Habib, R. J. (2025) · Oncology Letters · doi:10.3892/ol.2025.14989 · Cited by 17
Silva, J. L., de Andrade, G. C., Petronilho, E. C., de Sousa, G. D. S., Mota, M. F., Quarti, J., Guedes-da-Silva, F. H., Ferretti, G. D. S., Rangel, L. P., Vieira, T. C. R. G., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70055 · Cited by 12
“To overcome these limitations, PRIMA-1 was modified through methylation to create APR-246, a derivative with enhanced cell permeability, greater apoptotic efficacy (Bykov et al. 2005), and promising tolerability (Lehmann et al. 2012).”
Honoki, K., & Tsujiuchi, T. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.820010 · Cited by 13
p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie · doi:10.1002/ange.200600611 · Cited by 16
New Paradigms in the Clinical Management of Li–Fraumeni Syndrome
Giovino, C., Subasri, V., Telfer, F., & Malkin, D. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041584 · Cited by 11
Prima-1 and APR-246 in Cancer Therapy
Zatloukalová, P., Galoczová, M., & Vojtěšek, B. (2018) · Klinicka onkologie · doi:10.14735/amko20182s71 · Cited by 11
Sadahiro, Y., Hitora, Y., & Tsukamoto, S. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00913 · Cited by 12
Targeted therapies in the management of metastatic bladder cancer.
Fassan, M., Trabulsi, E. J., Gomella, L. G., & Baffa, R. (2007) · PubMed Central · Cited by 11
Babikir, H. A., Afjei, R., Paulmurugan, R., & Massoud, T. F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.004 · Cited by 11
Subaşıoğlu, A., Güç, Z. G., Gür, E. Ö., Tekindal, M. A., & Atahan, K. (2022) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2022.2022-7-2 · Cited by 13
Lai, C. W., Xie, C., Raufman, J., & Xie, G. (2022) · Cancers · doi:10.3390/cancers14010219 · Cited by 10
McCubrey, J. A., Abrams, S. L., Steelman, L. S., Cocco, L., Ratti, S., Martelli, A. M., Lombardi, P., Gizak, A., & Duda, P. (2022) · Biomolecules · doi:10.3390/biom12020276 · Cited by 10
Natural products that target p53 for cancer therapy
Tsukamoto, S. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-025-01906-6 · Cited by 11
New developments in small molecules targeting p53 pathways in anticancer therapy
Cheok, C. F., & Lane, D. P. (2008) · Drug Development Research · doi:10.1002/ddr.20261 · Cited by 12
Kumbhar, N., Nimal, S., Patil, D., Kaiser, V. F., Haupt, J., & Gacche, R. N. (2023) · Scientific Reports · doi:10.1038/s41598-023-36872-0 · Cited by 8
Deep learning untangles the resistance mechanism of p53 reactivator in lung cancer cells
Lee, S. M., Han, Y.-H., & Cho, K. (2023) · iScience · doi:10.1016/j.isci.2023.108377 · Cited by 8
The Effect of Adenovirus-Mediated Gene Expression of FHIT in Small Cell Lung Cancer Cells
Zandi, R., Xu, K., Poulsen, H. S., Roth, J. A., & Ji, L. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.626475 · Cited by 8
ROS, Redox Regulation, and Anticancer Therapy
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 15
Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach
Zhang, W., Liu, Y., Luo, Y., Xu, J., Zhang, B., Feng, P., Guo, C. F., Wang, Y., Huang, Z., Kong, Q., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140765 · Cited by 9
Metadata
- Authors
- Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G
- Venue
- Oncogene
- Published
- 2005-02-28
- Volume
- 24
- Issue
- 21
- Pages
- 3484-3491
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2006422601
- Cited by
- 252
- References
- 19
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 16 · 2021: 21 · 2020: 14 · 2019: 12 · 2018: 18 · 2017: 7 · 2016: 16 · 2015: 11 · 2014: 7 · 2013: 9 · 2012: 11
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancerfonden
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- mutant p53 reactivation, cisplatin, drug synergy, apoptosis, chemoresistance, combination chemotherapy, xenograft tumor growth, SCID mice
- MeSH terms
- Adenocarcinoma, Animals, Aza Compounds, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Interactions, Humans, Lung Neoplasms, Mutation, Quinuclidines, Osteosarcoma, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Mice, SCID, Apoptosis, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.